Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2016

View Archived Issues

Aralez to acquire U.S. rights to Toprol-XL from AstraZeneca

Morphotek signs exclusive license agreement with Eurofarma Laboratiorios

English NICE recommends Tagrisso as second-line treatment for EGFR T790M-positive NSCLC

Recursion Pharmaceuticals completes series A funding round

Therapeutic potential of targeting of PLAUR/TLR4 interaction in TP53-positive cancers

Catabasis Pharmaceuticals completes target enrollment for part B of MoveDMD trial

TAK1 is a promising new target for osteoarthritis

FDA accepts IND application for ASN-003

Daiichi Sankyo enters collaboration with AgonOx to develop immuno-oncology target

EMA grants SME designation to Dipexium Pharmaceuticals

FDA grants breakthrough therapy designation to Actemra for giant cell arteritis

New BARDA contract supports advanced development of V-920 Ebola Zaire vaccine

Ocular Therapeutix initiates first phase III trial of OTX-TP for glaucoma and ocular hypertension

Merck & Co. patents PDE2A inhibitors

Heptares Therapeutics discloses muscarinic M1 and M4 receptor agonists

Bristol-Myers Squibb describes TNF-alpha antagonists

Turing and Washington University partner on toxoplasmosis

GlaxoSmithKline presents bromodomain inhibitors

The Vanderbilt University reports mGlu2 receptor negative allosteric modulators

Altor and NantKwest sign cancer immunotherapy codevelopment agreement

twoXAR collaborates with Mount Sinai researchers in diabetic nephropathy

Bone Therapeutics reports promising data on Allob from phase IIa spinal fusion trial

Riptide Bioscience executes CRDA with NCI

Slit3 shows potential as a therapeutic target in metabolic bone diseases

Dimerix reports positive safety data for phase II trial of DMX-200

Lrp6 may be a new PTH-activated aNAC target gene

FDA grants orphan drug designation to AbbVie's atrasentan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...